Tamarly Lists · Tuesday · Trial phase steps

3 medicines that moved to the next trial phase this week

3 medicines from company sponsors entered a higher trial phase in trials registered on ClinicalTrials.gov from 3 November 2026 to 9 November 2026; the 3 below lead by phase and trial size.

As of . Research from public records, not investment advice.

  1. SHR-3167 (Jiangsu HengRui Medicine Co., Ltd.): First Phase 3 trial, after Phase 2 trials. Diabetes Mellitus, Type 2, 680 participants planned.
  2. Navepegritide (Ascendis Pharma A/S): First Phase 3 trial, after Phase 2 trials. Hypochondroplasia, 81 participants planned.
  3. 0.5% AR100DP1 (Arjil Pharmaceuticals LLC): First Phase 2 trial, after Phase 1/2 trials. Dermatitis Atopic, 40 participants planned.

How this list is made

A medicine counts when a company sponsor registers a trial of it on ClinicalTrials.gov at a higher phase (Phase 2, 2/3 or 3) than any of its earlier trials of the same drug, on ClinicalTrials.gov or the EU trials register (CTIS). The lead drug of each trial is used; placebo and standard-of-care arms are left out, and drug names are compared without doses or forms. A line says first when no earlier trial of the drug at that phase exists on either register, from any sponsor, and new otherwise. A new trial is a registration, not a result.

Sources: ClinicalTrials.gov, EU Clinical Trials Information System (CTIS).

Get the free weekly round-up every MondayEvery Monday: the week's private raises, IPO filings and deals filed with the SEC, each with its filing, and the most covered news about those companies. No account needed.

See the latest edition